GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synairgen PLC (LSE:SNG) » Definitions » Institutional Ownership

Synairgen (LSE:SNG) Institutional Ownership : 0.05% (As of Mar. 02, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Synairgen Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Synairgen's institutional ownership is 0.05%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Synairgen's Insider Ownership is 0.48%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Synairgen's Float Percentage Of Total Shares Outstanding is 0.00%.


Synairgen Institutional Ownership Historical Data

The historical data trend for Synairgen's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synairgen Institutional Ownership Chart

Synairgen Historical Data

The historical data trend for Synairgen can be seen below:

2023-03-31 2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31
Institutional Ownership 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05

Synairgen Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Synairgen Business Description

Traded in Other Exchanges
Address
Southampton General Hospital, Tremona Road, Mailpoint 810, Level F, South Block, Southampton, GBR, SO16 6YD
Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, SG018, and others.

Synairgen Headlines

No Headlines